Alnylam Pharmaceuticals total non-operating income/expense for the twelve months ending September 30, 2024 was $-0.133B, a 10.43% decline year-over-year.
Alnylam Pharmaceuticals annual total non-operating income/expense for 2023 was $-0.151B, a 55.74% decline from 2022.
Alnylam Pharmaceuticals annual total non-operating income/expense for 2022 was $-0.342B, a 138.29% increase from 2021.
Alnylam Pharmaceuticals annual total non-operating income/expense for 2021 was $-0.143B, a 428.28% increase from 2020.
Alnylam Pharmaceuticals Total Non-Operating Income/Expense 2010-2024 | ALNY